BioInvent Q4 2023: Now a mid-stage clinical company - Redeye

Redeye reviews BioInvent’s fourth quarter. The company now has six active clinical programs with several readouts this year, which may be transformative for the company. In particular, three projects are set to be in phase IIa during the year, of which two (BI-1206 in NHL and BI-1808) will have phase IIa readouts.

Länk till analysen i sin helhet: https://www.redeye.se/research/984710/bioinvent-q4-2023-now-a-mid-stage-clinical-company?utm_source=finwire&utm_medium=RSS